Dawn Buratti
Foot & Ankle Surgery · Reseda, CANPI 1538215439
Payments from drug & device makers
What this record shows
This record is dominated by other: $3,720 of the $5,675 with a category attached, or 65.5%. Smith+Nephew accounts for 70.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $4,057 and has fallen 96.1% since, to $159 in 2025.
Across 40 payments — averaging $141.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$4K
- Amgen$676
- Cardiovascular Systems Inc.$272
- AbbVie$186
- Melinta Therapeutics, LLC$183
- Angiodynamics, Inc.$153
- plus $232 from 10 others
What the payments were for
- Food & beverage$1,95534%
- Other$3,72066%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 5 | $3,973 |
| Amgen(2 entities) | 10 | $676 |
| Cardiovascular Systems Inc. | 3 | $272 |
| AbbVie | 4 | $186 |
| Melinta Therapeutics, LLC | 4 | $183 |
| Angiodynamics, Inc. | 2 | $153 |
| Paratek Pharmaceuticals, Inc. | 3 | $61 |
| GRT US Holding, Inc. | 1 | $32 |
| Anika Therapeutics, Inc. | 1 | $22 |
| Bioventus LLC | 1 | $21 |
| DJO, LLC | 1 | $20 |
| Paragon 28, Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
| Stryker | 1 | $15 |
| Arthrosurface Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,675 in reported general payments places this provider in the 75th percentile of 1,126 foot & ankle surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tavaborole | 12 | $1,401 |
| Terbinafine Hcl | 12 | $116 |
| Meloxicam | 14 | $32 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Reseda
- Eric GizaSacramento$3.6M
- Thomas HarrisPasadena$3M
- Thomas ChangSanta Rosa$2M
- Michael CoughlinSan Francisco$1.6M
- Vladimir ZeetserEncino$677K
- Jason NowakRedding$526K
- Candice BradyCamarillo$462K
- Andrew HsuOrange$456K
- Eric TanLos Angeles$447K
- Joseph ParkBurbank$387K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.